Vivek Kumar Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vivek Kumar Singh has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Mohane Selvaraj Coumar
Department of Bioinformatics, School of Life Sciences, Pondicherry University, Kalapet, India
5 shared publications - Hsing-Pang Hsieh
Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 35053, Taiwan, ROC
3 shared publications Akhil C. Banerjea
National Institute of Immunology
2 shared publications- Benson Chellakkan Selvanesan
The University of Texas MD Anderson Cancer Center 1 Department of Translational Molecular Pathology Houston, Texas
2 shared publications Hui-Yi Shiao
B Institute of Biotechnology and Pharmaceutical Research , National Health Research Institutes , 35 Keyan Road, Zhunan, Miaoli County 350 , Taiwan, ROC
2 shared publicationsJohn T. A. Hsu
Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli County 350, Taiwan, ROC
2 shared publications
Latest Publications
- 11 July 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (3) , 1119-1127
Leukaemic stem cell burden enhances prognostic precision in the non‐adverse European LeukemiaNet risk group of acute myeloid leukaemia
Summary: Leukaemic stem cells (LSCs) are chemo‐resistant leukaemia‐initiating clones that drive refractoriness and relapse in acute myeloid leukaemia (AML). The study evaluated the prognostic significance of LSC burden in treatment naïve AML patients. LSCs were quantified using Next‐generation flow cytometry; patients were stratified into LSC neg/low and LSC high groups based on the median LSC percentage, and correlated with post‐induction morphological remission and measurable residual disease (MRD) status, and long‐term outcomes including relapse‐free survival (RFS), event‐free survival (EFS) and overall survival (OS). LSCs were detectable in 93.5% patients, with a median frequency of 0.386%. Patients with LSC neg/low (≤0.386%) had higher rates of complete remission (CR) ( p = 0.05) and MRD negativity ( p = 0.002). Lower LSC burden was associated with improved RFS, EFS and OS (all p < 0.05) suggesting the prognostic relevance of LSC quantitation in AML. In both Cluster of Differentiation 34 positve (CD34+) and CD34 negative (CD34−) AML, low LSC% was associated with superior survival outcomes ( p < 0.05). LSC burden is a strong, independent predictor of response and survival in AML, and its integration with European LeukemiaNet risk‐stratification and MRD assessment may enhance risk refinement and individualized therapy.
- 11 July 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (3) , 1119-1127
Leukaemic stem cell burden enhances prognostic precision in the non‐adverse European LeukemiaNet risk group of acute myeloid leukaemia
Summary: Leukaemic stem cells (LSCs) are chemo‐resistant leukaemia‐initiating clones that drive refractoriness and relapse in acute myeloid leukaemia (AML). The study evaluated the prognostic significance of LSC burden in treatment naïve AML patients. LSCs were quantified using Next‐generation flow cytometry; patients were stratified into LSC neg/low and LSC high groups based on the median LSC percentage, and correlated with post‐induction morphological remission and measurable residual disease (MRD) status, and long‐term outcomes including relapse‐free survival (RFS), event‐free survival (EFS) and overall survival (OS). LSCs were detectable in 93.5% patients, with a median frequency of 0.386%. Patients with LSC neg/low (≤0.386%) had higher rates of complete remission (CR) ( p = 0.05) and MRD negativity ( p = 0.002). Lower LSC burden was associated with improved RFS, EFS and OS (all p < 0.05) suggesting the prognostic relevance of LSC quantitation in AML. In both Cluster of Differentiation 34 positve (CD34+) and CD34 negative (CD34−) AML, low LSC% was associated with superior survival outcomes ( p < 0.05). LSC burden is a strong, independent predictor of response and survival in AML, and its integration with European LeukemiaNet risk‐stratification and MRD assessment may enhance risk refinement and individualized therapy.
- 11 June 2016
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 35 (8) , 1833-1848
Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors
Chronic myeloid leukemia (CML) is caused by chromosomal rearrangement resulting in the expression of Bcr-Abl fusion protein with deregulated Abl tyrosine kinase activity. Approved drugs – imatinib, dasatinib, nilotinib, and ponatinib – target the ATP-binding site of Abl kinase. Even though these drugs are initially effective, long-term usefulness is limited by the development of resistance. To overcome this problem, targeting the allosteric site of Abl kinase, which is remote from the ATP-binding site is found to be a useful strategy. In this study, structure-based and ligand-based virtual screening methods were applied to narrow down possible drugs (from DrugBank database) that could target the allosteric site of Abl kinase. Detailed investigations of the selected drugs in the allosteric site of Abl kinase, using molecular dynamics and steered molecular dynamics simulation shows that gefitinib, an EGFR inhibitor approved for the treatment of lung cancer, could bind effectively to the allosteric site of Bcr-Abl. More interestingly, gefitinib was found to enhance the ability of imatinib to bind at the ATP-binding site of Bcr-Abl kinase. Based on the in silico findings, gefitinib was tested in combination with imatinib in K562 CML cell line using MTT cell proliferation assay and found to have a synergistic antiproliferative activity. Further detailed mechanistic study could help to unravel the full potential of imatinib – gefitinib combination for the treatment of CML.
- 11 June 2016
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 35 (8) , 1833-1848
Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors
Chronic myeloid leukemia (CML) is caused by chromosomal rearrangement resulting in the expression of Bcr-Abl fusion protein with deregulated Abl tyrosine kinase activity. Approved drugs – imatinib, dasatinib, nilotinib, and ponatinib – target the ATP-binding site of Abl kinase. Even though these drugs are initially effective, long-term usefulness is limited by the development of resistance. To overcome this problem, targeting the allosteric site of Abl kinase, which is remote from the ATP-binding site is found to be a useful strategy. In this study, structure-based and ligand-based virtual screening methods were applied to narrow down possible drugs (from DrugBank database) that could target the allosteric site of Abl kinase. Detailed investigations of the selected drugs in the allosteric site of Abl kinase, using molecular dynamics and steered molecular dynamics simulation shows that gefitinib, an EGFR inhibitor approved for the treatment of lung cancer, could bind effectively to the allosteric site of Bcr-Abl. More interestingly, gefitinib was found to enhance the ability of imatinib to bind at the ATP-binding site of Bcr-Abl kinase. Based on the in silico findings, gefitinib was tested in combination with imatinib in K562 CML cell line using MTT cell proliferation assay and found to have a synergistic antiproliferative activity. Further detailed mechanistic study could help to unravel the full potential of imatinib – gefitinib combination for the treatment of CML.
- Open Access
- 29 June 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , srep11702
Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification
The inhibition of FMS-like tyrosine kinase 3 (FLT3) activity using small-molecule inhibitors has emerged as a target-based alternative to traditional chemotherapy for the treatment of acute myeloid leukemia (AML). In this study, we report the use of structure-based virtual screening (SBVS), a computer-aided drug design technique for the identification of new chemotypes for FLT3 inhibition. For this purpose, homology modeling (HM) of the DFG-in FLT3 structure was carried using two template structures, including PDB ID: 1RJB (DFG-out FLT3 kinase domain) and PDB ID: 3LCD (DFG-in CSF-1 kinase domain). The modeled structure was able to correctly identify known DFG-in (SU11248, CEP-701 and PKC-412) and DFG-out (sorafenib, ABT-869 and AC220) FLT3 inhibitors, in docking studies. The modeled structure was then used to carry out SBVS of an HTS library of 125,000 compounds. The top scoring 97 compounds were tested for FLT3 kinase inhibition and two hits (BPR056, IC50 = 2.3 and BPR080, IC50 = 10.7 μM) were identified. Molecular dynamics simulation and density functional theory calculation suggest that BPR056 (MW: 325.32; cLogP: 2.48) interacted with FLT3 in a stable manner and could be chemically optimized to realize a drug-like lead in the future.
- 29 June 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , srep11702
Open AccessHomology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification
The inhibition of FMS-like tyrosine kinase 3 (FLT3) activity using small-molecule inhibitors has emerged as a target-based alternative to traditional chemotherapy for the treatment of acute myeloid leukemia (AML). In this study, we report the use of structure-based virtual screening (SBVS), a computer-aided drug design technique for the identification of new chemotypes for FLT3 inhibition. For this purpose, homology modeling (HM) of the DFG-in FLT3 structure was carried using two template structures, including PDB ID: 1RJB (DFG-out FLT3 kinase domain) and PDB ID: 3LCD (DFG-in CSF-1 kinase domain). The modeled structure was able to correctly identify known DFG-in (SU11248, CEP-701 and PKC-412) and DFG-out (sorafenib, ABT-869 and AC220) FLT3 inhibitors, in docking studies. The modeled structure was then used to carry out SBVS of an HTS library of 125,000 compounds. The top scoring 97 compounds were tested for FLT3 kinase inhibition and two hits (BPR056, IC50 = 2.3 and BPR080, IC50 = 10.7 μM) were identified. Molecular dynamics simulation and density functional theory calculation suggest that BPR056 (MW: 325.32; cLogP: 2.48) interacted with FLT3 in a stable manner and could be chemically optimized to realize a drug-like lead in the future.
- 1 December 2014
- Published by Springer Nature in Cellular Oncology
- Vol. 37 (6) , 439-454
Apoptosis induction by an analog of curcumin (BDMC-A) in human laryngeal carcinoma cells through intrinsic and extrinsic pathways
Head and neck cancer is the sixth most frequently occurring cancer worldwide and accounts for about 2 % of all cancer-related deaths annually. Curcumin is a well-known chemopreventive agent, and apoptosis induction by curcumin has been reported in many cancer cell types. We synthesized an ortho-hydroxy substituted analog of curcumin, bisdemethoxycurcumin analog (BDMC-A), and aimed to demarcate the apoptotic effects induced by BDMC-A on human laryngeal cancer Hep-2 cells and to compare these effects with those induced by curcumin. We evaluated the apoptotic effects of BDMC-A in comparison to those of curcumin on Hep-2 cells by performing Western blotting, RT-PCR, fluorescent staining and DNA fragmentation assays. In addition, we carried out an in silico molecular docking study on the EGFR kinase domain. We found that BDMC-A can induce apoptosis in Hep-2 cells by regulating the expression of both intrinsic and extrinsic apoptotic proteins, i.e., Bcl-2, Bax, apoptososme complex and death receptors, more efficiently than curcumin. We also observed increased nuclear fragmentation and chromatin condensation after BDMC-A treatment compared to curcumin treatment. Depolarized mitochondria and ROS generation was well pronounced in both BDMC-A and curcumin treated Hep-2 cells. Our in silico molecular docking study on the EGFR kinase domain revealed that BDMC-A may dock more efficiently than curcumin. From our results we conclude that BDMC-A can induce apoptosis in Hep-2 laryngeal carcinoma cells more effectively than curcumin, and that this activity can be attributed to the presence of a hydroxyl group at the ortho position within this compound.
- 1 December 2014
- Published by Springer Nature in Cellular Oncology
- Vol. 37 (6) , 439-454
Apoptosis induction by an analog of curcumin (BDMC-A) in human laryngeal carcinoma cells through intrinsic and extrinsic pathways
Head and neck cancer is the sixth most frequently occurring cancer worldwide and accounts for about 2 % of all cancer-related deaths annually. Curcumin is a well-known chemopreventive agent, and apoptosis induction by curcumin has been reported in many cancer cell types. We synthesized an ortho-hydroxy substituted analog of curcumin, bisdemethoxycurcumin analog (BDMC-A), and aimed to demarcate the apoptotic effects induced by BDMC-A on human laryngeal cancer Hep-2 cells and to compare these effects with those induced by curcumin. We evaluated the apoptotic effects of BDMC-A in comparison to those of curcumin on Hep-2 cells by performing Western blotting, RT-PCR, fluorescent staining and DNA fragmentation assays. In addition, we carried out an in silico molecular docking study on the EGFR kinase domain. We found that BDMC-A can induce apoptosis in Hep-2 cells by regulating the expression of both intrinsic and extrinsic apoptotic proteins, i.e., Bcl-2, Bax, apoptososme complex and death receptors, more efficiently than curcumin. We also observed increased nuclear fragmentation and chromatin condensation after BDMC-A treatment compared to curcumin treatment. Depolarized mitochondria and ROS generation was well pronounced in both BDMC-A and curcumin treated Hep-2 cells. Our in silico molecular docking study on the EGFR kinase domain revealed that BDMC-A may dock more efficiently than curcumin. From our results we conclude that BDMC-A can induce apoptosis in Hep-2 laryngeal carcinoma cells more effectively than curcumin, and that this activity can be attributed to the presence of a hydroxyl group at the ortho position within this compound.
- 26 October 2014
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 29 (1) , 89-100
Identification of ligand efficient, fragment-like hits from an HTS library: structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity
Furanopyrimidine 1 (IC50 = 273 nM, LE = 0.36, LELP = 10.28) was recently identified by high-throughput screening (HTS) of an in-house library (125,000 compounds) as an Aurora kinase inhibitor. Structure-based hit optimization resulted in lead molecules with in vivo efficacy in a mouse tumour xenograft model, but no oral bioavailability. This is attributed to “molecular obesity”, a common problem during hit to lead evolution during which degradation of important molecular properties such as molecular weight (MW) and lipophilicity occurs. This could be effectively tackled by the right choice of hit compounds for optimization. In this regard, ligand efficiency (LE) and ligand efficiency dependent lipophilicity (LELP) indices are more often used to choose fragment-like hits for optimization. To identify hits with appropriate LE, we used a MW cut-off 7 (IC50 = 852 nM, LE = 0.44, LELP = 8.36) with fragment-like properties suitable for further hit optimization. Moreover, hit 7 was found to be selective for Aurora A (Aurora B IC50 = 35,150 nM) and the possible reasons for selectivity investigated by docking two tautomeric forms (2H- and 3H-pyrazole) of 7 in Auroras A and B (PDB ID: 4AF3) crystal structures. This docking study shows that the major 3H-pyrazole tautomer of 7 binds in Aurora A stronger than in Aurora B. A series of in silico filters were applied to HTS library compounds, followed by biochemical testing identified aurora A selective hit 7 with fragment-like characters suitable for further development.
- 26 October 2014
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 29 (1) , 89-100
Identification of ligand efficient, fragment-like hits from an HTS library: structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity
Furanopyrimidine 1 (IC50 = 273 nM, LE = 0.36, LELP = 10.28) was recently identified by high-throughput screening (HTS) of an in-house library (125,000 compounds) as an Aurora kinase inhibitor. Structure-based hit optimization resulted in lead molecules with in vivo efficacy in a mouse tumour xenograft model, but no oral bioavailability. This is attributed to “molecular obesity”, a common problem during hit to lead evolution during which degradation of important molecular properties such as molecular weight (MW) and lipophilicity occurs. This could be effectively tackled by the right choice of hit compounds for optimization. In this regard, ligand efficiency (LE) and ligand efficiency dependent lipophilicity (LELP) indices are more often used to choose fragment-like hits for optimization. To identify hits with appropriate LE, we used a MW cut-off 7 (IC50 = 852 nM, LE = 0.44, LELP = 8.36) with fragment-like properties suitable for further hit optimization. Moreover, hit 7 was found to be selective for Aurora A (Aurora B IC50 = 35,150 nM) and the possible reasons for selectivity investigated by docking two tautomeric forms (2H- and 3H-pyrazole) of 7 in Auroras A and B (PDB ID: 4AF3) crystal structures. This docking study shows that the major 3H-pyrazole tautomer of 7 binds in Aurora A stronger than in Aurora B. A series of in silico filters were applied to HTS library compounds, followed by biochemical testing identified aurora A selective hit 7 with fragment-like characters suitable for further development.